| Autor: |
KEFELİ, Umut, KAYMAZ, Samet, AYDIN, Dinçer, IŞIK, Deniz, ÇABUK, Devrim, SONKAYA, Alper, AÇIKGÖZ, Özgür, IŞIK, Ulaş, ÖZDEN, Ercan, UYGUN, Kazım |
| Předmět: |
|
| Zdroj: |
Bezmialem Science; Oct2019, Vol. 7 Issue 4, p265-270, 6p |
| Abstrakt: |
Objective: Early-stage non-small cell lung cancer (NSCLC) constitutes approximately 25-30% of newly diagnosed lung cancers. Elderly patients with NSCLC have generallly been underrepresented in clinical studies. We explored adjuvant chemotherapy results in patients ≥65 years with early-stage NSCLC. Methods: The medical records of 111 elderly patients with early-stage NSCLC were reviewed retrospectively. Collected data included demographic information, clinical assessments and information on treatment. Survival was estimated using the Kaplan-Meier method and prognostic factors were evaluated with log-rank and Cox regression tests. Results: The median disease-free survival (DFS) was 22.6 months. In univariate analysis, significant association between stage, performance score (PS), adjuvant chemotherapy and DFS was detected (p<0.05). Stage, PS and adjuvant chemotherapy were found to have significant effects on overall survival (OS) (p<0.05). The median survival for the entire group was 41.6 months. Multivariate analysis showed that stage, PS and adjuvant chemotherapy affected both DFS and OS. Conclusion: Survival of elderly patients with early-stage NSCLC was significantly influenced by stage, PS and adjuvant chemotherapy. These factors, rather than age, should be considered in the treatment planning for elderly patients with NSCLC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
